MedTrace Logo

Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial

NCT03107078 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-04-18

No results posted yet for this study

Summary

For patients with active moderate-to-severe thyroid associated ophthalmopathy (TAO), the Intravenous Glucocorticoids (GCs) is the recommended therapy. However, the efficacy of GCs is not satisfied. Investigators established a novel classification of TAO for the first time to assess more precisely for better personal treatment.

Conditions

  • Thyroid Associated Ophthalmopathy

Interventions

DRUG

Glucocorticoids

Intravenous Glucocorticoids (GCs)

Sponsors & Collaborators

  • The Fifth Affiliated Hospital of Southern Medical University

    collaborator OTHER

  • Huadu District People's Hospital of Guangzhou

    collaborator OTHER

  • Zhujiang Hospital

    collaborator OTHER

  • Jie Shen

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2019-10-01
Completion
2021-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03107078 on ClinicalTrials.gov